Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rivas

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Journal of Pediatrics|February 24, 2006
Duration of illness is an important variable for untreated children with juvenile dermatomyositisLauren M Pachman, Kathy Abbott, James M Sinacore, et al.
Frontiers in Pharmacology|July 7, 2018
Cannabigerol Action at Cannabinoid CB<sub>1</sub> and CB<sub>2</sub> Receptors and at CB<sub>1</sub>-CB<sub>2</sub> Heteroreceptor ComplexesGemma Navarro, Katia Varani, Irene Reyes-Resina, et al.
Arthritis and Rheumatism|April 9, 2005
History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research RegistryLauren M Pachman, Rebecca Lipton, Rosalind Ramsey-Goldman, et al.
Annals of the Rheumatic Diseases|June 7, 2024
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension studyHermine I Brunner, Jonathan D Akikusa, Eslam Al-Abadi, et al.
The Journal of Clinical Investigation|December 25, 2019
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseasesAdriana A de Jesus, Yangfeng Hou, Stephen Brooks, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Journal of Pediatrics|February 24, 2006
Duration of illness is an important variable for untreated children with juvenile dermatomyositisLauren M Pachman, Kathy Abbott, James M Sinacore, et al.
Frontiers in Pharmacology|July 7, 2018
Cannabigerol Action at Cannabinoid CB<sub>1</sub> and CB<sub>2</sub> Receptors and at CB<sub>1</sub>-CB<sub>2</sub> Heteroreceptor ComplexesGemma Navarro, Katia Varani, Irene Reyes-Resina, et al.
Arthritis and Rheumatism|April 9, 2005
History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research RegistryLauren M Pachman, Rebecca Lipton, Rosalind Ramsey-Goldman, et al.
Annals of the Rheumatic Diseases|June 7, 2024
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension studyHermine I Brunner, Jonathan D Akikusa, Eslam Al-Abadi, et al.
The Journal of Clinical Investigation|December 25, 2019
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseasesAdriana A de Jesus, Yangfeng Hou, Stephen Brooks, et al.
Pageof 6